I-Mab’s Ragistomig Shows Promise in Phase 1 Trials
Company Announcements

I-Mab’s Ragistomig Shows Promise in Phase 1 Trials

I-MAB (IMAB) has released an update.

I-Mab, a biotech company specializing in cancer immunotherapies, has revealed promising Phase 1 clinical data for its PD-L1x4-1BB bispecific antibody, Ragistomig, indicating a manageable safety profile and significant efficacy in patients previously treated with checkpoint inhibitors. With one complete response and multiple partial responses observed in heavily pre-treated patients, the company is set to present these findings at the ASCO 2024 and is optimistic about the potential of Ragistomig as a new treatment option for cancer patients resistant to current therapies.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskI-Mab Appoints New CEO to Drive Cancer Therapy Goals
TheFlyI-Mab names Sean Fu as permanent CEO
TheFlyInhibrx prevails in trade secret case with I-Mab
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App